Adolfo Ferrando, MD, PhD, Professor at the Institute for Cancer Genetics, Columbia University, joins the Samuel Waxman Cancer Research Foundation’s Scientific Advisory Board
|Adolfo Ferrando, M.D., Ph.D.|
The Samuel Waxman Cancer Research Foundation (SWCRF) announced that Adolfo Ferrando, M.D., Ph.D., Professor at the Institute for Cancer Genetics at Columbia University, has joined its Scientific Advisory Board (SAB). Dr. Ferrando, who continues his role at Columbia University, will join his fellow SAB members at the SWCRF Breakthroughs Scientific Review and Symposium on April 29 and April 30, which marks the annual evaluation of SWCRF funded research programs.
“I’m delighted to welcome Adolfo Ferrando to the SWCRF scientific advisory board,” said Dr. Samuel Waxman, M.D., Founder and CEO of the Samuel Waxman Cancer Research Foundation. “Dr. Ferrando brings an impressive track record of research in high-risk leukemias and lymphomas to our brain trust of collaborators and we are looking forward to his contributions to our grants review process.”
The SWCRF SAB, together with the Foundation’s scientific leaders, evaluates grant proposals submitted by scientists with NCI-approved research programs. The board includes Lorraine Gudas, Ph.D., Chair of Pharmacology at Weill Cornell Medical Center, Robert A. Hromas, M.D., F.A.C.P., Dean of the Joe R. and Teresa Lozano Long School of Medicine at University of Texas Health, Ramon Parsons, M.D., Ph.D., Director of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, Nancy Speck, Ph.D., Professor of Cell and Developmental Biology at the University of Pennsylvania, Martin S. Tallman, M.D., Chief of Leukemia Service, Memorial Sloan Kettering Cancer Center, and Hua Yu, Ph.D., Professor of Cancer Immunotherapeutics and Tumor Immunology, City of Hope NCI Comprehensive Cancer Center.
The SWCRF’s scientific leadership includes Samuel Waxman, M.D., Founder and CEO, Jonathan D. Licht, M.D., SWCRF Chief Scientific Officer, and Alan G. Rosmarin, M.D., SWCRF Chief Mission Officer.
The SWCRF Breakthroughs Scientific Review and Symposium brings together the Institute Without Walls, a network of the foundation’s funded scientists working collaboratively throughout the United States and abroad on research projects that identify and correct abnormal gene function that causes cancer. This research is the basis for developing minimally toxic treatments for patients. The network includes scientists from leading cancer research institutions, including Dana-Farber Cancer Institute, Johns Hopkins University, Memorial Sloan Kettering Cancer Center, the Icahn School of Medicine at Mount Sinai and Weill Cornell Medical Center, among many others.
About Adolfo Ferrando, M.D., Ph.D.
Adolfo Ferrando, MD, PhD, Institute for Cancer Genetics, Columbia University, is Professor of Pediatrics and Pathology & Cell Biology, Associate Director for Research in the Pediatric Oncology Division and Director of the Lymphoid Development and Malignancies Program at the Herbert Irving Comprehensive Cancer Center. Dr. Ferrando received his MD and PhD from the University of Oviedo in Spain and completed his postdoctoral training at Dana Farber Cancer Research Institute in Boston. Dr. Ferrando’s research program combines genomics, biochemical, genetic and experimental therapeutics approaches towards the identification of novel therapies for the treatment of high risk leukemias and lymphomas. He has been the recipient of several honors and awards, most recently the Pershing Square Sohn Prize for Young Investigators in Cancer Research in 2014 and the V National "Doctores Diz Pintado" Cancer Research Prize in 2015. He is a member of several professional organizations including the American Society of Clinical Investigation and serves in numerous scientific review panels including the Basic Mechanisms of Cancer Therapeutics Study Section at the NIH.